These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8713682)

  • 1. Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro.
    Denny WA; Rewcastle GW; Bridges AJ; Fry DW; Kraker AJ
    Clin Exp Pharmacol Physiol; 1996 May; 23(5):424-7. PubMed ID: 8713682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.
    Rewcastle GW; Denny WA; Bridges AJ; Zhou H; Cody DR; McMichael A; Fry DW
    J Med Chem; 1995 Sep; 38(18):3482-7. PubMed ID: 7658435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA
    J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor.
    Bhattacharya SK; Cox ED; Kath JC; Mathiowetz AM; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Richter DT; Su C; Wessel MD
    Biochem Biophys Res Commun; 2003 Jul; 307(2):267-73. PubMed ID: 12859950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases.
    Denny WA
    Farmaco; 2001; 56(1-2):51-6. PubMed ID: 11347967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site.
    Arteaga CL; Ramsey TT; Shawver LK; Guyer CA
    J Biol Chem; 1997 Sep; 272(37):23247-54. PubMed ID: 9287333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors.
    Boschelli DH
    Curr Top Med Chem; 2002 Sep; 2(9):1051-63. PubMed ID: 12171571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.
    Palmer BD; Trumpp-Kallmeyer S; Fry DW; Nelson JM; Showalter HD; Denny WA
    J Med Chem; 1997 May; 40(10):1519-29. PubMed ID: 9154973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural determinants for potent, selective dual site inhibition of human pp60c-src by 4-anilinoquinazolines.
    Tian G; Cory M; Smith AA; Knight WB
    Biochemistry; 2001 Jun; 40(24):7084-91. PubMed ID: 11401553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.
    Wakeling AE; Barker AJ; Davies DH; Brown DS; Green LR; Cartlidge SA; Woodburn JR
    Breast Cancer Res Treat; 1996; 38(1):67-73. PubMed ID: 8825124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.
    Hennequin LF; Thomas AP; Johnstone C; Stokes ES; Plé PA; Lohmann JJ; Ogilvie DJ; Dukes M; Wedge SR; Curwen JO; Kendrew J; Lambert-van der Brempt C
    J Med Chem; 1999 Dec; 42(26):5369-89. PubMed ID: 10639280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.
    Bridges AJ; Zhou H; Cody DR; Rewcastle GW; McMichael A; Showalter HD; Fry DW; Kraker AJ; Denny WA
    J Med Chem; 1996 Jan; 39(1):267-76. PubMed ID: 8568816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of the epidermal growth factor receptor protein tyrosine kinase: a quantitative structure-activity relationship analysis.
    Singh P; Kumar R
    J Enzyme Inhib; 1998 Apr; 13(2):125-34. PubMed ID: 9629532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,4-dioxane-fused 4-anilinoquinazoline as inhibitors of epidermal growth factor receptor kinase.
    Lee JY; Park YK; Seo SH; So IS; Chung HK; Yang BS; Lee SJ; Park H; Lee YS
    Arch Pharm (Weinheim); 2001 Nov; 334(11):357-60. PubMed ID: 11822173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irreversible inhibitors of the erbB family of protein tyrosine kinases.
    Denny WA
    Pharmacol Ther; 2002; 93(2-3):253-61. PubMed ID: 12191617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
    J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors.
    Lü S; Zheng W; Ji L; Luo Q; Hao X; Li X; Wang F
    Eur J Med Chem; 2013 Mar; 61():84-94. PubMed ID: 22867529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.
    Ismail RSM; Abou-Seri SM; Eldehna WM; Ismail NSM; Elgazwi SM; Ghabbour HA; Ahmed MS; Halaweish FT; Abou El Ella DA
    Eur J Med Chem; 2018 Jul; 155():782-796. PubMed ID: 30047410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.